2 active not recruiting, 2 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 2 | Completed 2 |
Follow Mark Stein: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer ADXS-504 - Recurrent Prostate Cancer | Phase 1 | Completed | Mark Stein | 8 | 2021-08-12 | 2026-09-25 |
| CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition Cabozantinib, Nivolumab, Cytoreductive nephrectomy - Kidney Cancer, Renal Cell Carcinoma | Phase 2 | Active not recruiting | Mark Stein | 38 | 2020-06-22 | 2026-06-05 |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer REGN2810, Degarelix, Leuprolide Acetate - Prostate Cancer Metastatic | Phase 2 | Active not recruiting | Mark Stein | 26 | 2019-05-16 | 2025-04-25 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Nivolumab, Degarelix, BMS-986253 - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Completed | Mark Stein | 59 | 2018-10-11 | 2026-10-15 |
Prostatic Neoplasms (3) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Neoplasms (1)
Nivolumab (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · Docetaxel (1) · HuMax-IL8 (1) · Leuprolide (1) · cabozantinib (1) · cemiplimab (1)
United States (4)
Mark N. Stein, MD (3) · Mark N Stein, MD (1)